|
|
| (2 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{drugbox |
| | #REDIRECT [[Cefotaxime sodium]] |
| |width=300
| |
| |IUPAC_name = (6''R'',7''R'',''Z'')-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-<br>2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]<br>oct-2-ene-2-carboxylic acid
| |
| |CAS_number = 63527-52-6
| |
| | ATC_prefix=J01
| |
| | ATC_suffix=DD01
| |
| | PubChem=456256
| |
| | DrugBank=APRD00854
| |
| | C = 16 | H = 17 | N = 5 | O = 7 | S = 2
| |
| |molecular_weight = 455.47 g/mol
| |
| |bioavailability = n/a
| |
| |metabolism = [[Liver|Hepatic]]
| |
| |elimination_half-life = 0.8–1.4 hours
| |
| |excretion = 50–85% [[Kidney|renal]]
| |
| |pregnancy_AU = B1
| |
| |pregnancy_US = B
| |
| |legal_AU = S4
| |
| |routes_of_administration = [[intravenous therapy|Intravenous]]
| |
| }}
| |
| {{SI}}
| |
| {{EH}}
| |
| | |
| '''Cefotaxime''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[kɛfəˈtæksim, sɛfə-]}}) is a third-generation [[cephalosporin]] [[antibiotic]]. Like other third-generation cephalosporins, it has broad spectrum activity against [[Gram positive]] and [[Gram negative]] [[bacteria]]. In most cases, it is considered to be equivalent to [[ceftriaxone]] in terms of safety and efficacy. '''Cefotaxime sodium''' is marketed under various trade names including '''Claforan''' ([[Sanofi-Aventis]]).
| |
| | |
| ==Mechanism of Action==
| |
| Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.<ref>http://www.merck.com/mmpe/lexicomp/cefotaxime.html
| |
| </ref>
| |
| | |
| ==Clinical use==
| |
| Treatment of susceptible infection in respiratory tract, skin and skin structure, bone and joint, urinary tract, gynecologic as well as septicemia, and documented or suspected meningitis. Active against most gram-negative bacilli (not Pseudomonas) and gram-positive cocci (not enterococcus). Active against many penicillin-resistant pneumococci<ref>http://www.merck.com/mmpe/lexicomp/cefotaxime.html
| |
| </ref>. Also see{{main|Cephalosporin}}
| |
| | |
| ==Chemistry==
| |
| The ''syn''-configuration of the [[methoxy]][[imino]] moiety confers stability to [[beta lactamase|β-lactamase]] enzymes produced by many [[Gram-negative]] bacteria. Such stability to β-lactamases increases the activity of cefotaxime against otherwise resistant Gram-negative organisms.
| |
| | |
| | |
| | |
| ==External links==
| |
| | |
| | |
| {{CephalosporinAntiBiotics}}
| |
| | |
| [[Category:Cephalosporin antibiotics]]
| |
| | |
| [[pl:Cefotaksym]]
| |
| [[pt:Cefotaxima sódica]]
| |
| [[th:เซฟโฟแทกซิม]]
| |
| ==References==
| |
| 1. http://www.merck.com/mmpe/lexicomp/cefotaxime.html
| |
| {{SIB}}
| |
| {{WikiDoc Help Menu}}
| |
| {{WS}}
| |